Bank of America Corp /DE/ filed a Schedule 13G with the SEC on October 28, 2026, disclosing beneficial ownership of 2,133,861 shares of Jasper Therapeutics, Inc. Voting Common Stock as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Bank of America Corp /DE/ reported aggregate beneficial ownership of 2,133,861 shares of Jasper Therapeutics, Inc. Voting Common Stock.
  • Percent of class: The reported position represents 6.4% of the outstanding shares of the class.
  • Shared voting and dispositive power: All 2,133,861 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Triggering date: The date of the event requiring the filing is stated as September 30, 2026.
  • Share count basis: According to the filing, the percentage calculation relies on 33,274,561 outstanding shares disclosed in a Form DEFA14A filed by the issuer on October 19, 2026, reporting share totals as of September 28, 2026.
  • Filing entities: The statement is filed by Bank of America Corporation on behalf of itself and wholly owned subsidiaries BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International.

Bank of America's Schedule 13G Filing on Jasper Therapeutics Voting Common Stock

Bank of America Corp /DE/, organized in Delaware and headquartered at 100 N Tryon St, Charlotte, NC 28255, filed a Schedule 13G disclosing its beneficial ownership position in Jasper Therapeutics, Inc. (CUSIP 471871202), a company with principal executive offices at 2200 Bridge Pkwy Suite #102, Redwood City, California 94065. The filing was signed by Monica Yako as Authorized Signatory and dated October 28, 2026.

According to the filing, Bank of America is classified as a parent holding company or control person (Type HC) under the applicable schedule rules. The statement covers three wholly owned subsidiaries: BofA Securities, Inc., identified as a broker-dealer registered under section 15 of the Act; Bank of America N.A., identified as a bank under section 3(a)(6) of the Act; and Merrill Lynch International, identified as a non-U.S. institution. All 2,133,861 shares are attributed to shared voting power and shared dispositive power, with zero shares attributed to sole voting or sole dispositive power.

The filing includes a certification that, to the best of the signatory's knowledge and belief, "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities," as stated in Item 10 of the Schedule 13G. The 6.4% percentage is calculated against 33,274,561 outstanding shares, as disclosed in the issuer's own Form DEFA14A filed October 19, 2026.

What Was Disclosed

Bank of America Corp /DE/ disclosed beneficial ownership of 2,133,861 shares of Jasper Therapeutics, Inc. Voting Common Stock, representing 6.4% of the class, with all shares held under shared voting and dispositive power as of September 30, 2026.